ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0280

Compliance and Validation of Patient Reported Outcome Information Collected from Lupus Patients Using a Mobile Application

Kristy Bell1, Claire Dykas1, Hope Rainey1, Maggy Comberg1, Mary Mora1 and Peter Lipsky1, 1AMPEL BioSolutions LLC., Charlottesville, VA

Meeting: ACR Convergence 2020

Keywords: clinical trial, Measurement Instrument, Outcome measures, Patient reported outcomes, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Patient Reported Outcomes (PROs) can provide critical data in measuring the impact of a disease on an individual as well as the quality of response to treatment.  However, PROs are oftentimes recorded intermittently and require patients to recall a period of several weeks or months.  As a result, important PRO information may not always be representative of the complete recall period.  The development of mobile technology to collect PRO data in an electronic format (ePRO) allows for more frequent assessment in real time and in the person’s regular environment.  The goal of this study was to assess the compliance and equivalence of a smart phone application (app) in collecting PRO data in individuals SLE.

Methods: A smart phone app was developed that collects ePRO data from various instruments, including the Fatigue Severity Scale (FSS), Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F), Short Form Health Survey (SF-36), Patient Reported Outcome Measurement Information System (PROMIS-29), Systemic Lupus Activity Questionnaire (SLAQ), and LupusPRO.  Additionally, the duration of morning stiffness as well as patient global assessment (PtGA), pain and fatigue using a 10 cm visual analog scale were collected.  Information was collected as part of a multicenter randomized interventional clinical trial of patients who met ACR criteria for the classification of SLE (NCT03098823). ePRO information was collected daily (PtGA, fatigue, pain, morning stiffness), 5-days per week (FSS, FACIT-F), or weekly (SF-36, PROMIS-29, SLAQ, LupusPRO), and biometric data (steps, sleep and location) was recorded daily with the app or a linked smart watch.  Additionally, all PRO instruments were completed on seven occasions at the clinical sites utilizing both the app and standard paper forms separated by a distraction.  To determine agreement between information collected with the app and the paper-administered PROs, intra-class correlation coefficients (ICCs), paired student’s t-tests, and Bland-Altman plots for data collected at each of the seven site visits were evaluated.  Compliance, demographic information and Cronbach’s alpha as a measure of survey reliability were also assessed.

Results: For the 62 subjects from diverse ancestral backgrounds, compliance with ePRO completion was high for all PRO surveys ( >75%; Figure 1).  Cronbach’s alpha values for each PRO ranged from 0.74 to 0.96 for the ePROs, and 0.70 to 0.96 for the paper versions, suggesting moderate to high inter-survey reliability in measuring the targeted concepts.  Of the 168 ICC values computed from each site visit for each survey, 41 were indicative of moderate (0.5 to 0.75), 69 good (0.75 to 0.9) and 55 excellent ( >0.90) reliability between measurement methods (Table 1).  Bland-Altman plots verified method agreement with 151 of the pairwise comparisons yielding an insignificant difference.

Conclusion: The high rate of compliance in collecting ePROs and the high level of consistency between data collected by paper and electronic methods of administration indicate that the app provides highly reliable information capable of cataloging real-time changes in PROs in SLE patients.

Compliance with PRO instruments collected with a mobile app.

Top 15 intraclass correlation coefficients (ICCs) and respective 90% confidence intervals.


Disclosure: K. Bell, None; C. Dykas, None; H. Rainey, None; M. Comberg, None; M. Mora, None; P. Lipsky, Horizon Therapeutics, 3.

To cite this abstract in AMA style:

Bell K, Dykas C, Rainey H, Comberg M, Mora M, Lipsky P. Compliance and Validation of Patient Reported Outcome Information Collected from Lupus Patients Using a Mobile Application [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/compliance-and-validation-of-patient-reported-outcome-information-collected-from-lupus-patients-using-a-mobile-application/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/compliance-and-validation-of-patient-reported-outcome-information-collected-from-lupus-patients-using-a-mobile-application/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology